Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)

被引：0
|
作者：
Ioka, T. [1 ]
Nakamori, S. [2 ]
Sugimori, K. [3 ]
Kanai, M. [4 ]
Ikeda, M. [5 ]
Ozaka, M. [6 ]
Furukawa, M. [7 ]
Okusaka, T. [8 ]
Kawabe, K. [9 ]
Furuse, J. [10 ]
Komatsu, Y. [11 ]
Sato, A. [12 ]
Shimizu, S. [13 ]
Chugh, P. [14 ]
Tang, R. [15 ]
Ueno, M. [16 ]
机构：
[1] Osaka Int Canc Inst, Dept Canc Survey & Gastrointestinal Oncol, Osaka, Japan
[2] NHO Osaka Natl Hosp, Dept Surg, Osaka, Japan
[3] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Kanagawa, Japan
[4] Kyoto Univ Hosp, Dept Med Oncol, Kyoto, Japan
[5] Hosp East, Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan
[6] Canc Inst Hosp JFCR, Dept Gastroenterol, Tokyo, Japan
[7] NHO Kyushu Canc Ctr, Dept Gastroenterol Hepatol Pancreatol, Fukuoka, Fukuoka, Japan
[8] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[9] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka, Fukuoka, Japan
[10] Kyorin Univ, Fac Med, Dept Med Oncol, Mitaka, Tokyo, Japan
[11] Hokkaido Univ Hosp, Canc Ctr, Sapporo, Hokkaido, Japan
[12] Hirosaki Univ Hosp, Dept Oncol, Hirosaki, Aomori, Japan
[13] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[14] Servier Pharmaceut, Clin Sci, Boston, MA USA
[15] Servier Pharmaceut, Biostat & Programming, Boston, MA USA
[16] Kanagawa Canc Ctr, Hepatobiliary & Pancreat Med Oncol Div, Dept Gastroenterol, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
132P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy of liposomal-irinotecan (nal-IRI) plus 5-fluorouracil/folinic acid (5-FU/LV) versus oxaliplatin plus fluoropyrimidines in previous gemcitabine treated pancreatic adenocarcinoma (PAC) patients (pts).
    Kieler, Markus
    Unseld, Matthias
    Bianconi, Daniela
    Scheithauer, Werner
    Prager, Gerald W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [2] Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Shan, Y-S.
    Jameson, G. S.
    Macarulla, T.
    Lee, K-H.
    Cunningham, D.
    Blanc, J-F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Braiteh, F.
    Belanger, B.
    Bayever, E.
    de Jong, F.
    von Hoff, D. D.
    Siveke, J. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone
    Hubner, R. A.
    Chen, L-T.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Lee, K-H.
    Cunningham, D.
    Siveke, J. T.
    Braiteh, F. S.
    de Jong, F. A.
    Belanger, B.
    Walls, R.
    Mody, P. D.
    von Hoff, D. D.
    Wang-Gillam, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy.
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
    Ueno, Makoto
    Nakamori, Shoji
    Sugimori, Kazuya
    Kanai, Masashi
    Ikeda, Masafumi
    Ozaka, Masato
    Furukawa, Masayuki
    Okusaka, Takuji
    Kawabe, Ken
    Furuse, Junji
    Komatsu, Yoshito
    Ishii, Hiroshi
    Sato, Atsushi
    Shimizu, Satoshi
    Chugh, Priti
    Tang, Rui
    Ioka, Tatsuya
    CANCER MEDICINE, 2020, 9 (24): : 9396 - 9408
  • [7] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.
    Pelzer, Uwe
    Blanc, Jean-Frederic
    Melisi, Davide
    Cubillo, Antonio
    Von Hoff, Daniel D.
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Siveke, Jens T.
    Wan, Yin
    Solem, Caitlyn T.
    Botteman, Marc
    Yang, Yoojung
    de Jong, Floris
    Hubner, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A phase 1/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC).
    Dean, Andrew Peter
    Wainberg, Zev A.
    Ramanathan, Ramesh K.
    Boland, Patrick McKay
    Mody, Kabir
    Zhang, Bin
    Belanger, Bruce
    de Jong, Floris A.
    Braun, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Shan, Yang-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    Von Hoff, Daniel D.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy
    Pelzer, U.
    Blanc, J. -F
    Melisi, D.
    Cubillo, A.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L. -T
    Siveke, J. T.
    Wan, Y.
    Solem, C. T.
    Botteman, M.
    Yang, Y.
    de Jong, F.
    Hubner, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 260 - 260
12345